12:00 AM
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MA09-hRPE cells: Phase I/II amended

Advanced Cell said it will amend an open-label, dose-escalation, U.K. Phase I/II trial of MA09-hRPE cells to include patients with a visual acuity of 20/100. Previously, only SMD patients with a visual acuity...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >